Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren added to conventional therapy in type 2 diabetes with high cardiovascular and renal risk
2007-000860-25Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Aliskiren + conventional therapy with Placebo + conventional therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Started May 2007; status: terminated.
02
Drugs
aliskiren
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-000860-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000860-25.